Cargando…
Evaluation of a polymorphism in MYBPC3 in patients with anthracycline induced cardiotoxicity
Cardiotoxicity is the most serious side effect of anthracyclines (doxorubicin, daunorubicin or epirubicin). The incidence of anthracycline induced late cardiac toxicity (AIC) that is overt clinically is 3–5% in the Indian population. Polymorphism in intron 32 (deletion of 25 bp) of MYBPC3 has been s...
Autores principales: | Vinodhini, M. Thirumalai, Sneha, S., Nagare, R.P., Bindhya, S., Shetty, V., Manikandan, D., Ganesan, P., Sagar, T.G., Ganesan, T.S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5993918/ https://www.ncbi.nlm.nih.gov/pubmed/29716714 http://dx.doi.org/10.1016/j.ihj.2017.07.001 |
Ejemplares similares
-
Cardiotoxicity of Anthracyclines
por: Cardinale, Daniela, et al.
Publicado: (2020) -
Anthracycline Chemotherapy and Cardiotoxicity
por: McGowan, John V, et al.
Publicado: (2017) -
Evaluation of biomarkers for cardiotoxicity of anthracyclin-based chemotherapy
por: Broeyer, F. J. F., et al.
Publicado: (2008) -
The role of iron in anthracycline cardiotoxicity
por: Gammella, Elena, et al.
Publicado: (2014) -
Updates in Anthracycline-Mediated Cardiotoxicity
por: Nebigil, Canan G., et al.
Publicado: (2018)